Targeting the pi3k/akt/mtor signaling pathway in lung cancer: An update regarding potential drugs and natural products

N/ACitations
Citations of this article
108Readers
Mendeley users who have this article in their library.

Abstract

Lung cancer is one of the most common cancers and has a high mortality rate. Due to its high incidence, the clinical management of the disease remains a major challenge. Several reports have documented a relationship between the phosphatidylinositol‐3‐kinase (PI3K)/ protein kinase B (AKT)/ mammalian target of rapamycin (mTOR) pathway and lung cancer. The recognition of this pathway as a notable therapeutic target in lung cancer is mainly due to its central involvement in the initiation and progression of the disease. Interest in using natural and synthetic medications to target these signaling pathways has increased in recent years, with promising results in vitro, in vivo, and in clinical trials. In this review, we focus on the current understanding of PI3K/AKT/mTOR signaling in tumor development. In addition to the signaling pathway, we high-lighted the therapeutic potential of recently developed PI3K/AKT/mTOR inhibitors based on pre-clinical and clinical trials.

Cite

CITATION STYLE

APA

Iksen, Pothongsrisit, S., & Pongrakhananon, V. (2021, July 1). Targeting the pi3k/akt/mtor signaling pathway in lung cancer: An update regarding potential drugs and natural products. Molecules. MDPI AG. https://doi.org/10.3390/molecules26134100

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free